NCT07361315 Development and Online Evaluation of an Online Course for Parasomnias
| NCT ID | NCT07361315 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Manitoba |
| Condition | Sleep Terror |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-11-14 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2025-11-14 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Parasomnias are unwanted events during sleep. These refer to sleep terrors, sleepwalking, sleep eating, nightmares, and movement during REM sleep. There are few systematic behavioral treatments for these problems and individuals with them often receive little education about self-management. This research examines and evaluates the effectiveness of a 4 week online course providing education and guidance about managing parasomnias. The primary outcomes are improvement in parasomnia frequency and distress. The secondary outcomes are improvements in work and social adjustment, mood, anxiety, stress level, fatigue, sleepiness, insomnia, and cognitive interference.
Eligibility Criteria
Inclusion Criteria: * physician referred for parasomnia * meet criteria for parasomnia on the Structured Clinical Interview for Sleep Disorders (SCISD-R) * age \>= 18 years * parasomnia duration \>= 6 months * English reading, sighted * access to device. Exclusion Criteria: * currently taking one of Lithium, Thioridazine, Chlorpromazine, Perphenazine, Methaqualone, Amitriptyline, Selective Serotonin Re-Uptake Inhibitors, Serotonin and Norepinephrine Re-Uptake inhibitors, or Zopiclone * seizure or major neurological disorder * untreated sleep apnea, restless legs syndrome, or narcolepsy
Contact & Investigator
Norah Vincent, PhD
PRINCIPAL INVESTIGATOR
University of Manitoba
Frequently Asked Questions
Who can join the NCT07361315 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sleep Terror. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07361315 currently recruiting?
Yes, NCT07361315 is actively recruiting participants. Contact the research team at csantos17@hsc.mb.ca for enrollment information.
Where is the NCT07361315 trial being conducted?
This trial is being conducted at Winnipeg, Canada.
Who is sponsoring the NCT07361315 clinical trial?
NCT07361315 is sponsored by University of Manitoba. The principal investigator is Norah Vincent, PhD at University of Manitoba. The trial plans to enroll 20 participants.